Treats acne vulgaris. ANDA 210004, held by Taro. Clindamycin Phosphate.
As of Nov 15, 2026, ANDA 210004 (Clindamycin Phosphate), held by Taro, was first approved by FDA on Mar 11, 2020, with 0 approved supplements and 0 published complete response letters.
Clindamycin phosphate foam is indicated for topical application in the treatment of acne vulgaris in patients 12 years and older. Clindamycin phosphate foam is a lincosamide product indicated for acne vulgaris in patients 12 years and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clindamycin Phosphate1% · aerosol, foam;topical | Clindamycin Phosphate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
